MARKETWIRE.NET

Decode Your Next Market Move

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global Induced Pluripotent Stem Cells (iPSCs) market. Market segmentation includes by Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types); by Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods); by Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications).

Find Out More About Regions, Brands, Dominant, Active & Niche Companies Covered in the Report

24 November 5:55 a.m., Silicon Valley, California - According to the new market research report, the global market for Induced Pluripotent Stem Cells (iPSCs) is projected to reach US$2.4 Billion by the year 2027, encouraged by the growing focus on exploiting iPSCs to develop novel drugs for the treatment of diseases. iPSCs are slated to witness substantial growth in the coming years due to increasing research funding, technical breakthroughs, and therapeutic potential of these cells. iPSCs present a unique therapeutic approach for treatment of various diseases minus ethical concerns. The domain has witnessed technical breakthroughs in recent years to improve cellular reprogramming & differentiation and large-scale production of desired GMP-grade iPSCs derived cells for clinical applications. iPSCs are receiving huge R&D investments from governments and private organizations for exploring novel application areas. The market growth is also driven by increasing announcement of new clinical trials involving these cells to find treatment for various diseases. While the foremost human iPSC trial was launched in 2014, recent trials have indicated potential of iPSCs derived from retinal pigmented epithelial cells in treating macular degeneration. Japan is witnessing various physician-led studies intended to explore iPSC-derived therapies to treat heart disease, Parkinson`s disease, macular degeneration and human platelet production.

Driven by advancing iPSC technology, it is possible to generate large amounts of disease specific IPSCs from heterogeneous backgrounds. Such cells are further differentiated into disease relevant cell types, which demonstrate disease phenotype akin to primary cells, which suffer from limited proliferation and are also difficult to access. The panel of disease specific IPSCs along with their derivatives are capable of enabling high throughput screening assays compared to a large library of compounds. Such an approach is capable of enabling development of new therapeutics and facilitates deriving of cell types such as hepatocytes and cardiomyocytes from iPSCs of patients. These properties are poised to play a vital role in assessing drug toxicities in early drug development stages, thus saving time and cost and lowering the use of animals for drug testing purposes. Research related disease specific IPSCs for drug screening purposes have been conducted in case of neuronal diseases and metabolic liver diseases.

The iPSCs are emerging as ideal platforms for developments in cardiovascular precision medicine, due to their ability to enable generation of patient-specific somatic cells. Drug therapy and discovery for cardiovascular diseases, despite substantial advancements over the years, continues to lag behind other fields such as oncology. The lack of drug discovery in the space is mainly attributed to the lack of reproducible and efficient translational model systems. Most existing drug discovery and testing platforms depend on animal studies and animal-based clinical trials, which often suffer from drawbacks due to differences among the species. The flaws in clinical trials are also attributed to the assumption that individuals suffering from one type of disease respond to a therapy in an identical manner, without taking into account factors such as epigenomic and genetic variations that contribute to the individuality. However, driven by continuous advances in phenotyping and differentiation methods, patient-specific iPSC derived cardiovascular cells are emerging to present considerable potential for development or discovery of new drug targets as well as for screening of new compounds intended for cardiovascular disease treatment. iPSCs, which come integrated with an individual's genetic information, are capable of considerably improving the process of efficient testing of drugs, and also for creation of personalized drug therapy for individuals.

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. All analysis and findings published in the report are based on validated engagements from a total executive pool size of 1737. Among this pool, 313 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 69 unique participations, a total of 31 validated responses were received as part of this report's primary research outreach program.

Key Competitors Covered in the Report -
Thermo Fisher Scientific, Inc.
Lonza Group Ltd.
Evotec AG
Takara Bio, Inc.
Stemcell Technologies Canada, Inc.
Abcam PLC
Horizon Discovery Group PLC
Cell Signaling Technology, Inc.
Cell Applications, Inc.
Invivogen
ReproCELL, Inc.
FUJIFILM Cellular Dynamics, Inc.

Segments Covered in the Report -
Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types)
Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods)
Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications)

Geographies Analyzed in the Report -
World
USA
Canada
Japan
China
Europe
France
Germany
Italy
UK
Rest of Europe
Asia-Pacific
Rest of World.

View Executive Engagement Dashboards, COVID Impact Questionnaires & Get Complimentary Access to Methodology & Full-Text Secondary Sources

For enquiries e-mail us at sales@strategyR.com .

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world`s only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com